Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98410 | 0.90 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Hydrochloric Acid SCHEMBL10584588 | 0.89 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Water SCHEMBL27625510 | 0.89 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28176484 | 0.86 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL607047 | 0.85 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL2176024 | 0.85 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL15255033 | 0.84 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17479413 | 0.84 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5052765 | 0.84 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5052771 | 0.84 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | Changchun Changcheng Pharmaceutical Technology Co., LTD (CN) | 2025-12-02 | — | — | US | disclosed |
| CN-114206894-B | Prodrug platform useful for delivery of amines, amides and phenols | 长春长乘医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-3820879-B1 | PHOSPHORUS-CONTAINING PRODRUGS OF GEMCITABINE | CHANGCHUN CHANGCHENG PHARMACEUTICAL TECH CO LTD (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118453872-A | Method for treating lower urinary tract urothelial cancer | 塔里斯生物医药公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118354759-A | Compositions comprising 2' -deoxycytidine analogs and their use for treating sickle cell disease, thalassemia and cancer | 阿基拉比奥有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240112752-A1 | METHODS AND SYSTEMS FOR ANNOTATING GENOMIC DATA | Martingale Labs, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-20240112813-A1 | METHODS AND SYSTEMS FOR ANNOTATING GENOMIC DATA | Martingale Labs, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | AKIRABIO, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023069529-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-1831237-A1 | AMIDE PRODRUG OF GEMCITABINE, COMPOSITIONS AND USE THEREOF | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1781788-A2 | CHICKEN DEOXYCYTIDINE AND DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGene A/S (DK) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006065525-A1 | AMIDE PRODRUG OF GEMCITABINE, COMPOSITIONS AND USE THEREOF | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-1646716-A1 | YELLOW FEVER MOSQUITO DEOXYRIBONUCLEOSIDE KINASES AND ITS USE | ZGene A/S (DK) | 2006-04-19 | — | — | EP | disclosed |
| WO-2006002627-A9 | CHICKEN DEOXYCYTIDINE AND DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGENE AS (DK) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006002627-A2 | CHICKEN DEOXYCYTIDINE AND DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGENE A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | disclosed |
| EP-1520015-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | Knecht, Wolfgang (SE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005626-A1 | YELLOW FEVER MOSQUITO DEOXYRIBONUCLEOSIDE KINASES AND ITS USE | ZGENE A/S (DK) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004003185-A2 | PLANT DEOXYRIBONUCLEOSIDE KINASE ENZYMES AND THEIR USE | KNECHT WOLFGANG (SE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | TYMP, HBZ, CDA | SLC28A1 165/4885SLC28A2 67/4885SLC29A1 37/4885 |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | SLC28A1 171/4885SLC28A2 72/4885SLC29A1 39/4885 |
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | GOT1, PAM, GLS2 | SLC28A1 227/4885SLC28A2 340/4885SLC29A1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.